If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The city of Sibiu, with its Brukenthal National Museum, was selected as the 2007 European Capital of Culture and the 2019 European Region of Gastronomy. Multiple castles exist in Romania, including the popular tourist attractions of Peleș Castle, Corvin Castle, and Bran Castle or "Dracula's Castle".
== Other species == All mammals have an extremely closely related blood coagulation process, using a combined cellular and serine protease process. It is possible for any mammalian coagulation factor to "cleave" its equivalent target in any other mammal. The only non-mammalian animal known to use serine proteases for blood coagulation is the horseshoe crab. Exemplifying the close links between coagulation and inflammation, the horseshoe crab has a primitive response to injury, carried out by cells known as amoebocytes (or hemocytes) which serve both hemostatic and immune functions.
The top-down approach is breaking down of a system into small components, while bottom-up is assembling sub-systems into a larger system. A bottom-up approach for nano-assembly is a primary research target for nano-fabrication because top down synthesis is expensive (requiring external work) and is not selective on very small length scales, but is currently the primary mode of industrial fabrication. Generally, the maximum resolution of the top-down products is much coarser than those of bottom-up; therefore, an accessible strategy to bridge "bottom-up" and "top-down", is realizable by the principles of self-assembly. By controlling local intermolecular forces to find the lowest-energy configuration, self-assembly can be guided by templates to generate similar structures to those currently fabricated by top-down approaches. This so-called bridging will enable fabrication of materials with the fine resolution of bottom-up methods and the larger range and arbitrary structure of top-down processes. Furthermore, in some cases components are too small for top-down synthesis, so self-assembly principles are required to realize these novel structures. Classification Nanostructures can be organized into groups based on their size, function, and structure; this organization is useful to define the potential of the field. By size Among the more sophisticated and structurally complex nanostructures currently available are organic macromolecules, wherein their assembly relies on the placement of atoms into molecular or extended structures with atomic-level precision.
American Bells - A guide to the species in subgenus Viorna American Clematis Society Clematis viorna images at bioimages.vanderbilt.edu Clematis virginiana images at bioimages.vanderbilt.edu International Clematis Society "Clematis" . The American Cyclopædia. 1879. The Clematis., one of the Flowers of Loveliness for 1838 with an illustration (Clematis) by Thomas Uwins combined with poetry (The Clematis) by Letitia Elizabeth Landon.
Sources: en.wikipedia.org
The increase in the fraction of estradiol bound to SHBG results in a significant decrease in the percentage of free or unbound and hence bioactive estradiol. As a result, the bioavailability and potency of oral estradiol may be diminished relative to parenteral estradiol routes by some amount. However, a study found that the free fraction of estradiol was similar with doses of oral and topical estradiol that resulted in equivalent total estradiol levels.
The samples were found to be "masses of virtually pure collagen" and not to have the "biochemical characteristics of invertebrate collagen, nor the collagen fiber arrangement of octopus mantle." The results suggest the samples are "the remains of the skin of an enormous warm-blooded vertebrate." The authors conclude that "there is no evidence to support the existence of Octopus giganteus" and concur with Verrill (1897) and Lucas (1897) that the St. Augustine carcass was "the remains of a whale, likely the entire skin [blubber layer] . . . nothing more or less."
=== Boers retreat === The set-piece period of the war now largely gave way to a guerrilla war, but one final operation remained. President Kruger and what remained of the Transvaal government had retreated to eastern Transvaal. Roberts, joined by troops from Natal under Buller, advanced against them, and broke their last defensive position at Bergendal on 26 August. As Roberts and Buller followed up along the railway line to Komatipoort, Kruger sought asylum in Portuguese East Africa (modern Mozambique). Some dispirited Boers did likewise, and the British gathered up much war material. However, the core of the Boer fighters under Botha easily broke back through the Drakensberg Mountains into the Transvaal highveld after riding north through the bushveld. As Roberts's army occupied Pretoria, the Boer fighters in the Orange Free State retreated into the Brandwater Basin, a fertile area in the south-east of the Republic. This offered only temporary sanctuary, as the mountain passes leading to it could be occupied by the British, trapping the Boers. A force under General Archibald Hunter set out from Bloemfontein to achieve this in July 1900. The hard core of the Free State Boers under De Wet, accompanied by President Steyn, left the basin early. Those remaining fell into confusion and most failed to break out before Hunter trapped them.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.